Search

Search Constraints

You searched for: Author/Creator Xia, Shuting

Search Results

1. Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial. Issue 3 (March 2023)

2. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Issue 10057 (5th November 2016)

6. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies. (21st May 2019)

8. Partial loss of psychiatric risk gene Mir137 in mice causes repetitive behavior and impairs sociability and learning via increased Pde10a. (December 2018)

10. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Issue 10063 (17th December 2016)